Background Ankylosing spondylitis (AS) is an inflammatory disease with documented elevated
cardiovascular (CV) risk due to systemic inflammation and a higher prevalence of CV risk …

Objective. We investigated changes in high-density lipoprotein (HDL) profiling in patients with
rheumatoid arthritis who started treatment by taking tumor necrosis factor (TNF) inhibitors. …

We read with interest the retrospective case-control study by de Jong et al.(1) The authors
found an intriguing association between statin use and development of rheumatoid arthritis (…

Background Rheumatoid arthritis (RA) is a chronic inflammatory joint disease which is
associated with an increased cardiovascular (CV) risk. It is still unknown to what extent this is due …

Background Adipose tissue is not inert, but has a not yet clearly understood immunomodulating
effect and may adversely impact treatment response in patients receiving anti-TNF …

Background Limited data is currently available regarding the pharmacokinetics (PK) and –dynamics
(PD) of tocilizumab (TCZ) in daily clinical practice. Objectives To assess the …

Background There is accumulating evidence that rheumatoid arthritis (RA) should be
considered as prothrombotic state, explaining the increased risk of thromboembolic events. …

Purpose: The aim of the study was to investigate differences in biomechanical factors and
activity limitations between knee and/or hip osteoarthritis (OA) patients with and without …

Background Tocilizumab (TCZ) inhibits interleukine-6 (IL-6) receptor resulting in inhibition
of C-Reactive Protein (CRP) production, a surrogate marker for IL-6 receptor blockade. …

Background Rheumatoid arthritis (RA) is a chronic inflammatory disease with an increased
cardiovascular (CV) risk. Carotid intima-media thickness (cIMT) predicts CV events in the …